To test this hypothesis, we additionally treated NPe6-PDT-R cells with trametinib, a clinically used inhibitor of MEK1/2 (upstream activator kinases of ERK1/2), simultaneously with NPe6-PDT and investigated whether trametinib reversed the resistance of GBM cells to NPe6-PDT. The gene discussed is MAPK3; the disease is glioblastoma.